Frovatriptan
Clinical data
Trade namesFrova
Other names6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
(6R)-6-methylamino-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
AHFS/Drugs.comMonograph
MedlinePlusa604013
Pregnancy
category
  • AU: B3
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability20–30%
MetabolismHepatic
Elimination half-life26 hours
ExcretionRenal
Identifiers
  • (+)-(R)-3-Methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H17N3O
Molar mass243.310 g·mol−1
3D model (JSmol)
  • CN[C@@H]3CCc2[nH]c1ccc(C(N)=O)cc1c2C3
  • InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1 checkY
  • Key:XPSQPHWEGNHMSK-SECBINFHSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Frovatriptan, sold under the brand name Frova, is a triptan drug developed by Vernalis for the treatment of migraine headaches[1] and for short term prevention of menstrual migraine.[2] The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[3]

Medical uses

Frovatriptan is used in the treatment of migraine.

Available forms

It is available as 2.5 mg tablets.

Contraindications

Frovatriptan should not be given to patients with:

  • Ischemic heart disease
  • Cerebrovascular syndrome
  • Peripheral vascular disease
  • Uncontrolled hypertension
  • Hemiplegic or basilar migraine

Side effects

Rare, but serious cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.

Pharmacology

Pharmacodynamics

Frovatriptan is a serotonin receptor agonist, with high affinity for the 5-HT1B/1D receptors. It has no significant effects on the GABAA mediated channel activity and benzodiazepine binding sites. Frovatriptan inhibits excessive dilation of arteries that supply blood to the head.

Pharmacokinetics

Frovatriptan has a terminal elimination half-life of approximately 26 hours, making it the longest within its class.[4]

Society and culture

US licensing

Frovatriptan is available only by prescription in the United States and Canada, where a secondary New Drug Approval (sNDA) was filed in July 2006.[5]

References

  1. ↑ Allais G, Benedetto C (2016). "Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine". Drug Design, Development and Therapy. 10: 3225–3236. doi:10.2147/DDDT.S105932. PMC 5055118. PMID 27757013.
  2. ↑ MacGregor EA (2014). "A review of frovatriptan for the treatment of menstrual migraine". International Journal of Women's Health. 6: 523–35. doi:10.2147/IJWH.S63444. PMC 4039425. PMID 24904224.
  3. ↑ "Frova". Vernalis. Archived from the original on 2007-09-27. Retrieved 2007-11-28.
  4. ↑ Balbisi, Ebrahim (September 2006). "Frovatriptan: A Review of Pharmacology, Pharmacokinetics and Clinical Potential in the Treatment of Menstrual Migraine". Therapeutics and Clinical Risk Management. 2 (3): 303–308. doi:10.2147/tcrm.2006.2.3.303. PMC 1936266. PMID 18360605.
  5. ↑ "Patient Information Sheet -- Frovatriptan succinate (marketed as Frova)". Food and Drug Administration. July 2006. Archived from the original on 2007-09-29. Retrieved 2007-11-28.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.